Page 1598 - Small Animal Internal Medicine, 6th Edition

1570 Index

Phenoxybenzamine, 733t–734t, 891, Pituitary-adrenocortical axis tests Pneumonia Polymorphic ventricular tachycardia, 41
896t–897t, 1185t–1186t (Continued) aspiration. see Aspiration pneumonia Polymyositis
Phentolamine, 217t description of, 864–871, 866t, 867b bacterial. see Bacterial pneumonia canine idiopathic, 1176
VetBooks.ir Phenylephrine hydrochloride low-dose dexamethasone suppression community-acquired, 340, 1441t diagnosis of, 1248t, 1253
characteristics of, 1252–1253
with clinical evidence of sepsis, 1441t
high-dose dexamethasone suppression
Phenylephrine, 386t–388t
test, 864–865, 866t, 871
feline idiopathic, 1176–1177
definition of, 340
in cats, 90t–91t
description of, 98
test, 864–865, 866t, 867–868, 869f
in dogs, 90t–91t urine cortisol/creatinine ratio, 866t, fungal, 344 immune-mediated, 1252–1253, 1253b
idiopathic interstitial, 349–352
infectious causes of, 1253b
dosage of, 90t–91t 867, 867f–868f, 881, 881t viral, 340–343 Polyneuropathies, 1163–1168
Phenylpropanolamine, 733t–734t Placental sites subinvolution, 976–977, Pneumonic plague, 1541 acquired chronic, 1164–1168
Phenytoin 976f Pneumonitis chronic idiopathic, 1165–1166
in cats, 90t–91t Plague, feline, 1460–1462, 1461f, 1461b, allergic, 201 chronic inflammatory demyelinating,
in dogs, 90t–91t 1541 eosinophilic, 201 1165, 1166f
dosage of, 90t–91t Plant alkaloids, 1273, 1273b heartworm disease as cause of, 201, congenital/inherited, 1163–1164,
toxic effects of, 93 Plantigrade posture, 832, 833f 206 1164b
Pheochromocytoma, 889–892 Plasma ammonia concentration, 536–537 Pneumonyssoides caninum, 244 diabetic, 1164, 1165f
clinical features of, 889–890 Plasma cells, 1211 Pneumoperitoneum, 419–420 hypothyroid, 1164–1165
description of, 862–864 Plasma oncotic pressure, 361 Pneumothorax, 376–377 insulinoma, 1165
diagnosis of, 890–891, 891t Plasma osmolality, 918 characteristics of, 364–365 paraneoplastic, 1165
etiology of, 889 Plasma protein C activity, 537 chest tubes as cause of, 367 Polyphagia with weight loss, 898–899,
hypertensive crisis caused by, 218 Plasma protein fraction, 1420 definition of, 364–365 899t
physical examination of, 890t Plasmacytoma, 448t radiographic findings of, 364–365, Polyps
prognosis for, 892 Plasmin, 222 365f nasopharyngeal
signs of, 890t Plasminogen activator inhibitor, 1388, spontaneous, 364–365, 376–377, 377f feline, 264, 264f
treatment of, 891–892 1405f thoracocentesis for, 345 peripheral vestibular disease caused
Pheromones, 728 Platelet(s) traumatic, 376 by, 1114
Phimosis, 993–996 activation of, 221 Poikilocytosis, 1345t radiographic signs of, 249f, 249b
Phlebotomy, for erythrocytosis, 116, adhesion of, 1387–1388 Point of maximal intensity (PMI), 7–8, rectal, 503–504
1369 aggregability of, 223, 1387–1388 10f Polysulfated glycosaminoglycans, 1196,
Phosphate supplementation dysfunction, 1397–1399, 1397b Polioencephalitis, 1122–1123 1197t, 1209t–1210t
diabetic ketoacidosis treated with, in Greyhounds, 1361 Pollakiuria, 649, 652, 736 Polyuria, 213, 519–522, 649, 653–656,
843–844 hyperaggregability of, 223 Polyarthritis, 1440t. see also Arthritis 654t–655t, 695, 695b, 740–741, 741t
hypophosphatemia treated with, Platelet count, 397–398, 412 breed-specific syndromes, 1205 Pons, 1037–1038
930–931, 930b Platelet-derived growth factor receptor, calicivirus, 1201, 1201f Pontine micturition center (PMC), 730
Phosphorus 1273 canine rheumatoid-like, 1206–1208, Portal hypertension
balance, 695–697 Platelet-rich plasma, 1355–1356 1206f–1207f chronic hepatitis and, 588
hormones that affect metabolism of, Platynosomum concinnum, 573b classification of, 1202b treatment of, 593–594, 594f
759t Plavix. see Clopidogrel clinical manifestations, 1187 noncirrhotic, 609f, 610–611
hyperphosphatemia, 691, 929–930, Plerixafor, 1494 diagnosis of, 1248t Portal vein, primary hypoplasia of,
929b Pleural cavity erosive, 1189, 1208 610–611
hypophosphatemia, 843–844, 930–931, computed tomography of, 366 familial, 1205 Portal vein thrombosis, 233
930b disorder of, 371–378 feline chronic progressive, 1245t Portal venous hypoplasia, 721
restriction, 700–701 chylothorax, 374–375, 375b feline periosteal proliferative, 1208, Portocaval shunt, congenital, 588f
Physaloptera rara, 463–465 mediastinal masses, 377–378, 377f 1208t Portosystemic shunt
Physiologic nystagmus, 1109 neoplastic effusion, 375–376 immune-mediated acquired, 588f
Physiotherapy, for bacterial pneumonia, pneumomediastinum, 378 breed-specific, 1245t congenital, 577–579, 578f, 603–609
343 pyothorax, 371–374, 372f clinical features of, 1245–1246, clinical features of, 604, 604f
Pilocarpine, 1172 disorders of, general considerations 1246b diagnosis of, 604–605, 604f
Pimobendan for, 360 cytologic findings, 1246, 1246f in dogs, 584, 603–609
chronic heart failure treated with, 63, radiography of, 364 diagnosis of, 1246, 1246f etiology and pathogenesis of, 603
64t, 69, 128 ultrasonography of, 366 erosive, 1208, 1245t hepatic encephalopathy in, 606–608,
congestive heart failure treated with, Pleural effusion etiology of, 1245 607b
63, 64t, 129, 201–202 chylous, 361t, 362f, 363 glucocorticoids for, 1203–1204, prognosis for, 605–606, 605f
dilated cardiomyopathy treated with, cytologic findings, 371, 373f 1204t, 1204b treatment for, 605–606
145, 170 diagnostic approach, 360–361, 361t, nonerosive, 1187, 1188f, 1202–1204, description of, 117
pulmonary hypertension treated with, 382 1202b, 1204t Posaconazole, 472, 1504t
193, 354 fluid classification, 360 noninfectious, 1189 Positional nystagmus, 1109
Pinch biopsy, 254–255, 254f hemorrhagic, 361t, 362f, 363–364 primary, 1245 Positional ventrolateral strabismus, 1111f
Pindolol, 94t modified transudates, 361–363, 362f signs of, 1246b Positive inotropic agents
Piroxicam neoplasia as cause of, 364 treatment of, 1246–1247 dilated cardiomyopathy treated with,
dosage of, 1268t nonseptic exudates, 361t, 362f, 363 infectious causes of, 1189t 169
joint disease treated with, 1209t–1210t pulmonary thromboembolism as Mycoplasma, 1199 heart failure treated with, 69–70
nasal tumors treated with, 265 cause of, 360 noninfectious, 1201–1206 Positive pressure, 385
Pituitary dwarfism, 753–757, 1033 radiographic findings, 360, 364–366, pain and, 1187 Postictal period, 1093
in cats, 786f 365f periosteal proliferative, 1189 Postobstructive diuresis, 654t–655t
clinical features of, 754 septic exudates, 361t, 362f, 363 reactive, 1189, 1201–1202, 1202f Postpartum disorders, 974–979
clinical pathology of, 754 thoracentesis for, 360 rickettsial, 1199–1200 eclampsia, 975–976
clinical signs of, 754, 754b, 755f thoracic radiographs of, 360 septic, 1443–1444 endometritis, 977–978, 977f
diagnosis of, 754–755, 756f, 756b thoracocentesis for, 167 systemic lupus erythematosus- inappropriate maternal behavior,
endocrine alopecia caused by, 748t transudates, 361–363, 361t, 362f induced, 1204–1205 974–975, 975f
etiology of, 753–754 ultrasonography of, 360, 366 Polychromasia, 1345t metabolic, 975–976
growth hormone therapy for, 755–757 Pleural fibrosis, 372f Polyclonal gammopathies, 1421, 1421b overview of, 974–979
lanugo retention associated with, 754 Pleural fissure lines, 364 Polycystic kidney disease, 693b placental sites subinvolution, 976–977,
prognosis for, 757 Pleural fluids Polycythemia, 1368 976f
signalment, 754 chylous, 361t, 362f, 363 Polycythemia rubra vera, 1368 uterine, 976–978
treatment of, 755–757 hemorrhagic, 362f, 363–364 Polydipsia, 213, 519–522, 649, 653–656, Postpartum metritis, 1034t–1036t
Pituitary gland, disorders of, 740–757 modified transudate, 361–363, 362f 654t–655t, 695, 740–741, 741t Postprandial hyperchylomicronemia, 909
Pituitary irradiation, 876–877, 876f nonseptic exudates, 361t, 362f, 363 psychogenic, 655–656, 741t, 746–747 Postrenal azotemia, 649
Pituitary macrotumor syndrome, septic exudates, 361t, 362f, 363 Polymerase chain reaction Postural reactions, 1046–1047, 1048f
859–860, 860f transudates, 361–363, 361t bartonellosis diagnosis using, 1457 Posture, 1043–1045, 1044f
Pituitary tumors, 877 Pleural space disease, 382 canine monocytotropic ehrlichiosis Potassium
Pituitary-adrenocortical axis, 858f Pleural thickening, 364 diagnosis using, 1476 hyperkalemia, 47–48, 49b, 50f,
Pituitary-adrenocortical axis tests Pleuroperitoneal shunts, 375–376 fecal analysis, 414 690–691, 919–921, 920b, 921t
adrenocorticotropic hormone Pleurovenous shunts, 375 infectious diseases, 1432–1433, 1432f hypokalemia, 47, 49b, 921–923, 922b,
stimulation test, 870, 870f Pneumomediastinum, 360, 365, 365f, lower respiratory tract disorders, 298 923t
in cats, 881–882 378 lymphoma diagnosis using, 1300 supplementation of